Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 2NET 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Breast Neoplasms 23Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 14Multiple Myeloma 14Neoplasm Metastasis 13Recurrence 10Melanoma 10Leukemia, Myeloid, Acute 10Colorectal Neoplasms 10Carcinoma, Renal Cell 10Lymphoma, Non-Hodgkin 9Leukemia, Lymphocytic, Chronic, B-Cell 9Urinary Bladder Neoplasms 8Lymphoma, Follicular 8Thyroid Neoplasms 7Hematologic Neoplasms 7Stomach Neoplasms 6Small Cell Lung Carcinoma 6Sarcoma 6Prostatic Neoplasms 6Ovarian Neoplasms 6Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma 6Lung Neoplasms 6Head and Neck Neoplasms 6Colonic Neoplasms 6Uterine Cervical Neoplasms 5Thyroid Cancer, Papillary 5

Interventions

lutetium Lu 177 dotatate 1copper dotatate CU-64 1belzutifan 1Lutetium-177 1Lutetium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Paraganglioma × 1 year × Clear all
NCT04924075 2026-05-28

MK-6482-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
322 enrolled 1 FDA
CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡